These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

115 related articles for article (PubMed ID: 11067500)

  • 1. On the evidence. Type 2 diabetes.
    Melville A; Richardson R; Lister-Sharp D
    Health Serv J; 2000 Mar; 110(5696):32-3. PubMed ID: 11067500
    [No Abstract]   [Full Text] [Related]  

  • 2. Complications of type 2 diabetes: renal disease and the promotion of patient self-management.
    Melville A; Richardson R; Lister-Sharp D
    Nurs Times; 2000 Apr 27-May 3; 96(17):37-8. PubMed ID: 11961775
    [No Abstract]   [Full Text] [Related]  

  • 3. Diabetes Mellitus Review.
    Blair M
    Urol Nurs; 2016; 36(1):27-36. PubMed ID: 27093761
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Should all Pima Indians with type 2 diabetes mellitus be prescribed routine angiotensin-converting enzyme inhibition therapy to prevent renal failure?
    Kiberd BA; Jindal KK
    Mayo Clin Proc; 1999 Jun; 74(6):559-64. PubMed ID: 10377929
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Should normotensive diabetic patients with microalbuminuria be treated with angiotensin converting enzyme inhibitors?].
    Feldt-Rasmussen BF
    Ugeskr Laeger; 2002 Apr; 164(14):1907-9. PubMed ID: 11957423
    [No Abstract]   [Full Text] [Related]  

  • 6. Cost-effectiveness of angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers in newly diagnosed type 2 diabetes in Germany.
    Adarkwah CC; Gandjour A
    Int J Technol Assess Health Care; 2010 Jan; 26(1):62-70. PubMed ID: 20059782
    [TBL] [Abstract][Full Text] [Related]  

  • 7. ACE inhibition and renovascular disease.
    Carr S
    Diabet Med; 2001 Jan; 18 Suppl 1():4-6. PubMed ID: 11289190
    [No Abstract]   [Full Text] [Related]  

  • 8. The CARI guidelines. Cost-effectiveness and socioeconomic implications of prevention and management of chronic kidney disease in type 2 diabetes.
    Chadban S; Howell M; Twigg S; Thomas M; Jerums G; Cass A; Campbell D; Nicholls K; Tong A; Mangos G; Stack A; MacIsaac RJ; Girgis S; Colagiuri R; Colagiuri S; Craig J;
    Nephrology (Carlton); 2010 Apr; 15 Suppl 1():S195-203. PubMed ID: 20591031
    [No Abstract]   [Full Text] [Related]  

  • 9. Nephropathy in patients with type 2 diabetes mellitus.
    Ritz E; Orth SR
    N Engl J Med; 1999 Oct; 341(15):1127-33. PubMed ID: 10511612
    [No Abstract]   [Full Text] [Related]  

  • 10. [Angiotensin converting enzyme inhibitors in the treatment of diabetes].
    Smahelová A
    Vnitr Lek; 2003 Dec; 49(12):948-51. PubMed ID: 15040161
    [No Abstract]   [Full Text] [Related]  

  • 11. Renin angiotensin system (RAS) blockade and diabetic microvascular complications in the eye and kidney.
    Bilous R
    Prim Care Diabetes; 2008 Dec; 2(4):201-2. PubMed ID: 18760685
    [No Abstract]   [Full Text] [Related]  

  • 12. Renal diseases in diabetes mellitus.
    Kumar PD; Rajaratnam K
    J Indian Med Assoc; 1997 Jul; 95(7):426-8. PubMed ID: 9425845
    [No Abstract]   [Full Text] [Related]  

  • 13. Combination therapy with angiotensin-converting enzyme inhibitors and angiotensin receptor antagonists in the treatment of patients with type 2 diabetes mellitus.
    Rosner MH; Okusa MD
    Arch Intern Med; 2003 May; 163(9):1025-9. PubMed ID: 12742799
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Diabetic nephropathy: introduction.
    Breyer MD
    Semin Nephrol; 2007 Mar; 27(2):129. PubMed ID: 17418681
    [No Abstract]   [Full Text] [Related]  

  • 15. [Renal histopathology of diabetic nephropathy].
    Suzuki Y
    Nihon Rinsho; 2005 Jun; 63 Suppl 6():314-9. PubMed ID: 15999726
    [No Abstract]   [Full Text] [Related]  

  • 16. [Can progression to terminal renal insufficiency be avoided in diabetic nephropathy?].
    Luño J; Valderrábano F
    An Med Interna; 1998 Nov; 15(11):567-71. PubMed ID: 9882851
    [No Abstract]   [Full Text] [Related]  

  • 17. Diabetes and ACE inhibitors.
    Boulton AJ; Gokal R
    J Hum Hypertens; 1990 Oct; 4 Suppl 4():63-6; discussion 66-7. PubMed ID: 2283656
    [No Abstract]   [Full Text] [Related]  

  • 18. Best practice for hypertensive patients with kidney disease.
    de Zeeuw D
    Hosp Med; 2003 Feb; 64(2):96-100. PubMed ID: 12619337
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Renoprotective effects of ACE inhibitors and AT1 antagonists on diabetic nephropathy beyond blood pressure control].
    Shionoiri H; Yasuda G; Takizawa T; Shionoiri F
    Nihon Rinsho; 2005 Jun; 63 Suppl 6():394-9. PubMed ID: 15999741
    [No Abstract]   [Full Text] [Related]  

  • 20. Clinical inquiries. Do ACE inhibitors prevent nephropathy in type 2 diabetes without proteinuria?
    Sferra L; Kelsberg G; Dodson S; Saseen J
    J Fam Pract; 2004 Jan; 53(1):68-9. PubMed ID: 14709273
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.